Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention

Headaches and migraines continue to be a leading cause of suffering and disability. As per the Global Burden of Disease Survey conducted in 2010, the exact magnitude of the disease still is underestimated. Migraine alone continues to rank seventh as a cause of disability. Various therapeutic modalit...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Shuchita, Vij, Malti, Edward, Neeraj, Vij, Brinder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Clinical Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047699/
https://www.ncbi.nlm.nih.gov/pubmed/32174669
http://dx.doi.org/10.4103/joacp.JOACP_3_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047699/
https://www.ncbi.nlm.nih.gov/pubmed/32174669
http://dx.doi.org/10.4103/joacp.JOACP_3_19

Ejemplares similares